Market Closed -
Other stock markets
|
After market 04:44:32 pm | |||
25.62 USD | -0.08% | 25.62 | -0.02% |
10:42pm | First trial over Zantac cancer claims set to begin in Chicago | RE |
05:18pm | Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The company is one of the best yield companies with high dividend expectations.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- One of the major weak points of the company is its financial situation.
- With an enterprise value anticipated at 3.21 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.01% | 145B | C+ | ||
+34.00% | 664B | C+ | ||
+29.29% | 567B | B | ||
-7.75% | 354B | C+ | ||
+18.53% | 330B | B- | ||
+4.95% | 286B | C+ | ||
+13.79% | 234B | B+ | ||
+4.93% | 199B | B- | ||
-9.78% | 196B | A+ | ||
-4.89% | 148B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PFE Stock
- Ratings Pfizer, Inc.